News coverage about Coherus BioSciences (NASDAQ:CHRS) has trended positive on Tuesday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Coherus BioSciences earned a daily sentiment score of 0.26 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.2200933883467 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Shares of Coherus BioSciences (NASDAQ CHRS) opened at 12.475 on Tuesday. Coherus BioSciences has a one year low of $10.80 and a one year high of $31.98. The company’s market capitalization is $640.54 million. The company has a 50-day moving average price of $13.15 and a 200 day moving average price of $17.85.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.29) by $0.21. The business had revenue of $1.40 million for the quarter. Coherus BioSciences had a negative return on equity of 307.41% and a negative net margin of 73.89%. Equities analysts anticipate that Coherus BioSciences will post ($5.13) EPS for the current year.

Several analysts have recently weighed in on CHRS shares. Maxim Group reduced their price target on Coherus BioSciences from $44.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, June 12th. Citigroup Inc. set a $38.00 price target on Coherus BioSciences and gave the stock a “buy” rating in a report on Wednesday, May 17th. Credit Suisse Group set a $38.00 price target on Coherus BioSciences and gave the stock a “buy” rating in a report on Monday, June 12th. J P Morgan Chase & Co restated a “buy” rating on shares of Coherus BioSciences in a report on Monday, June 12th. Finally, Zacks Investment Research upgraded Coherus BioSciences from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Tuesday, August 15th. Two investment analysts have rated the stock with a sell rating and ten have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $32.70.

WARNING: “Positive Media Coverage Somewhat Unlikely to Impact Coherus BioSciences (CHRS) Stock Price” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/12/positive-media-coverage-somewhat-unlikely-to-impact-coherus-biosciences-chrs-stock-price.html.

In other Coherus BioSciences news, insider Alan C. Herman sold 17,535 shares of Coherus BioSciences stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $15.02, for a total value of $263,375.70. Following the transaction, the insider now directly owns 49,651 shares of the company’s stock, valued at approximately $745,758.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 26.28% of the stock is owned by insiders.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Insider Buying and Selling by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.